AAV production leadership Virovek offers patented BAC-to-AAV and toxin-based cell ablation technologies with high-titer production capabilities, presenting a strong value proposition for organizations seeking scalable and customizable AAV vectors for research and development partnerships.

Licensing opportunities All proprietary technologies are available for non-exclusive licensing, enabling potential customers to access Virovek’s platform without exclusive commitments, which can accelerate collaboration with universities and biotech firms.

Global outreach Established customer base across the Americas and Eurasia with active interest in Africa and Oceania, suggesting expansion partnerships and regional service agreements could unlock new markets and multi-region collaborations.

Service diversification Current offerings include gene cloning, baculovirus production, and upcoming large-scale AAV production in HEK293 cells, indicating opportunities to upsell full-package workflows and scale-up services for translational projects.

Growth potential With revenue in the mid-range and a lean team, there is room to partner with contract manufacturers or larger biotech players to co-develop and co-commercialize AAV platforms, potentially expanding capacity and sales velocity.